Tarsus reports $145M Q1 XDEMVY sales (+85% YoY), receives $15M China milestone

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 net product sales reached $145.4M, up 85% from $78.3M in Q1 2025, driven by higher prescription volume and improved gross-to-net discounts. Company reaffirmed full-year 2026 guidance of $670-700M.

  Item 2.02 verify on EDGAR →
• high

  Received $15M regulatory milestone from China partner Grand Pharmaceuticals following XDEMVY approval in the People's Republic of China, recorded as $16.7M in collaboration revenue including withholding tax.

  Item 2.02 verify on EDGAR →
• high

  Q1 net loss narrowed to $7.0M ($0.16 per share) from $25.1M ($0.64 per share) in Q1 2025. Cash position stood at $388.7M as of March 31, 2026.

  Item 2.02 verify on EDGAR →